Quantitative US for Evaluation of Hepatic Steatosis in NAFLD
The Diagnostic Performance Assessment of Quantitative Ultrasound Imaging Indices for Differentiating Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease
Sponsor: Samsung Medison
Listed as NCT04462562, this NA trial focuses on Fatty Liver and Fatty Liver, Nonalcoholic and remains completed. Sponsored by Samsung Medison, it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Apr 2022 — Jul 2024 [monthly]
Completed NA
-
Sep 2021 — Apr 2022 [monthly]
Completed NA
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Apr 2021 — Sep 2021 [monthly]
Recruiting NA
-
Jan 2021 — Apr 2021 [monthly]
Recruiting NA
-
Sep 2020 — Jan 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Not Yet Recruiting NA
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Samsung Medison
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .